drugset / Trial / NCT06455826
MAD of IVT VP-001 in PRPF31 Mutation-Associated Retinal Dystrophy Subjects (Wallaby)
NaSequentialOpen-labelTreatment
Summary
A Phase 1 Open-Label, Multiple Ascending Dose Study to Evaluate the Safety and Tolerability of Intravitreally Administered VP-001 in Participants with Confirmed PRPF31 Mutation-Associated Retinal Dystrophy
Timeline
- Start
- 2024-06-13
- Primary completion
- 2025-09-24
- Completion
- 2025-09-24
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | VP-001 | Oligonucleotide (other) | 30 ug | Intravitreal |
| Subject | VP-001 | Oligonucleotide (other) | 75 ug | Intravitreal |